Floatz logo

EPA

Drug-Induced Dyskinesia

University of StellenboschSmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Drug-Induced Dyskinesia cohort.

Asset / SponsorPhaseRating
Levodopa
Sumitomo Pharma Co., Ltd.
Phase 4A
carbidopa
AbbVie (prior sponsor, Abbott)
Phase 4BBB
Amantadine
Adamas Pharmaceuticals, Inc.
Phase 3BBB
Emd 128130
EMD Serono
Phase 3BBB
1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)-
Novartis Pharmaceuticals
Phase 2BBB

View all 25 →

Same molecule, other indications

EPA is also rated in:

major depressive disorderDormant
BB
Indicative · Phase 2/3
68 / 100
View asset →
classic familial adenomatous polyposisDormant
BB
Indicative · Phase 3
66 / 100
View asset →
schizophreniaDormant
B
Indicative · Phase 4
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →